This study aims to define the morphological profile associated with the presence of donor-specific antibodies (DSAs) and/or C4d immunostaining in ABO-identical or compatible pediatric liver grafts. Ten-year protocol liver graft biopsies performed at 131.3 6 15.3 months after transplantation in 53 pediatric liver graft recipients were reviewed. Immunostaining for C4d was systematically performed and semiquantitatively analyzed. DSAs were concurrently quantified, and results were available for 44 patients. All biopsies demonstrated fibrotic changes with a mean liver allograft fibrosis score (LAFSc) of 5.1 6 2.2. A total of 31 (58%) biopsies exhibited C4d positivity. DSAs were detected in 20 (45%) patients, and mean maximal mean fluorescence intensity was 12,977 6 6731. LAFSc (6.3 6 1.3 versus 3.9 6 2.2; P 5 0.008), perivenular fibrosis (2.7 6 0.5 versus 1.3 6 1.0; P < 0.001), and portal inflammation (1.4 6 0.8 versus 0.3 6 0.5; P 5 0.009) were significantly higher in the double-DSA and C4d-positive group versus the double-negative group. We defined a histological scoring system from these results, which was integrated with the 2016 Banff definition and allowed reclassifying patients for the diagnosis of chronic active antibodymediated rejection (cAMR; 11/53 versus 13/53). Diagnoses of probable cAMR according to Banff 2016 (n 5 4) were unchanged, but 2 among the 9 patients classified as possible cAMR according to the 2016 Banff definition were excluded for this diagnostic when using our histological score. In conclusion, our results confirmed that perivenular fibrosis and portal inflammation in late pediatric liver graft biopsies are features of cAMR. Our histological score could improve the accuracy of the 2016 Banff definition for the diagnosis of cAMR.
Liver transplantation (LT) introduced in the 1970s is now a routine lifesaving treatment for fulminant or end-stage liver diseases and hepatocellular carcinoma. The longterm results are good with patient and graft survival rates of 62.4% and 57.6% at 10 years for adults (French Agency of Biomedicine Report, 2016) and 83% and 73% for children.
(1) The improvement of immunosuppressive regimens has dramatically decreased the incidence of classical ductopenic rejection. (2) Recently, several studies both in adults and children (3) (4) (5) (6) (7) (8) (9) (10) (11) raised the concept of chronic active antibody-mediated rejection (cAMR) in liver grafts, as described in other solid organ allografts; cAMR has recently been identified as a risk factor for liver graft outcome. (9, 12) In 2016, the Banff working group on liver allograft pathology proposed 4 criteria for the definition of probable cAMR:
1. Histological pattern of injury consistent with cAMR, requiring both of the following:
a. Otherwise unexplained and at least mild mononuclear portal and/or perivenular inflammation with interface and/or perivenular necroinflammatory activity. b. At least moderate portal/periportal, sinusoidal, and/or perivenular fibrosis.
2. Recent circulating human leukocyte antigen (HLA) donor-specific antibodies (DSAs) in serum samples. 3. At least focal C4d positivity (>10% portal tract microvascular endothelial). 4 . Reasonable exclusion of other insults that might cause a similar pattern of injury. (13) Similarly, possible cAMR is defined as above, but with minimal or absent C4d staining. Nevertheless, work is needed to better define DSA-associated tissue injury patterns because the very frequent recurrence of hepatitis C in adult liver recipients until recently has blurred the histological changes. (14) Pediatric recipients represent an "ideal model" to identify rejection-induced morphological lesions because they do not suffer from recurrence of the initial liver disease and are usually free of comorbidities. (13) This study based on a cohort of 53 liver pediatric ABO-identical or compatible recipients with a 10-year protocol biopsy aims to define the morphological changes specifically associated with the presence of DSA and/or C4d immunostaining in liver grafts, in order to refine the diagnosis criteria of cAMR.
Patients and Methods

PATIENTS
From January 2002 to December 2006, a total of 167 consecutive children underwent a first LT in the pediatric surgery unit of Bicêtre Hospital, Le KremlinBicêtre, France. Among them, 148 children survived for 10 years or more after transplantation. All were followed up in the pediatric hepatology unit of this hospital. A total of 53 children (male, n 5 30, 57%; female, n 5 23, 43%) underwent a more thorough investigation at 10 years after transplantation on the basis of the decision of their referring clinician. This 10-year checkup included abdominal imaging, percutaneous liver biopsy, and DSA test. This 10-year checkup included abdominal imaging, percutaneous liver biopsy, and DSA tests. Fifty-three patients, which were transplanted from January 2002 and December 2006, underwent the 10-year checkup between December 2011 and March 2016 (mean 6 standard deviation, time after LT, 131.3 6 15.3 months; median, 128 months; range, 114-202 months). All the 53 patients were included in the study. Written informed consent was obtained from the patient's parents at the time of biopsy. The study protocol received an a priori approval of our institutional review committee. Characteristics of the 53 patients are summarized in Table 1 . All grafts were ABO identical or compatible. Liver biochemistry tests were performed on blood samples harvested concurrently with the liver graft biopsy. Laboratory data included the following: serum aspartate aminotransferase (AST; normal range, <40 IU/L); serum alanine aminotransferase (ALT; normal range, <40 IU/L); total bilirubin (normal range, <17 lmol/L); gamma-glutamyl transpeptidase (GGT; normal range, <25 IU/L); immunoglobulin G (IgG); protidemia (normal range, 62-82 g/L); albuminemia (normal range, 35-45 g/L); prothrombin (normal range, >70%); and factor V (normal range, >70%). Five patients had liver test abnormalities at the time of the protocol biopsy.
HISTOLOGICAL REVIEW OF LIVER ALLOGRAFT BIOPSIES
Liver graft biopsies were processed for routine light microscopy. Biopsy samples were fixed in formalin, acetic acid, and alcohol; paraffin-embedded; and sliced 3-lm thick. Slides were stained with hematoxylin-eosin-saffron (HES), picrosirius red, and Perls' Prussian blue. All liver graft biopsies were reviewed in a blind manner to the clinical, biochemical, and serological data by 2 pathologists (M.D. and C.G.). Graft fibrosis was staged semiquantitatively according to the liver allograft fibrosis score (LAFSc) developed by Venturi et al. (15) Portal tract, sinusoidal, and perivenular fibrosis were thus staged separately from 0 to 3 (0 5 absent, 1 5 mild, 2 5 moderate, and 3 5 severe fibrosis), with a total score ranging from 0 to 9. The following criteria were systematically analyzed and semiquantified when applicable: quality of sample (size, number of portal tracts), liver plate architecture (normal, modified, or nodular), portal inflammation (0-3), portal vein endothelialitis (0-3), portal microvasculitis (0-3), lymphocytic cholangitis (yes/no), ductular proliferation (0-3, with or without neutrophils), bile duct dystrophy (yes/no), ductopenia (%), macrovesicular and mediovesicular steatosis (%), lobular inflammation (0-3), centrilobular perivenulitis (yes/no), centrilobular endothelialitis (0-3), and cholestasis (yes/no).
C4D IMMUNOHISTOCHEMICAL STAINING
Immunostaining for C4d was performed using a rabbit monoclonal A24-T anti-human C4d antibody (dilution 1/100; DB Biotech, Kosice, Slovakia) and a Leica BOND-MAX autostainer (Leica Biosystems Newcastle, Ltd., Newcastle, United Kingdom). Epitope retrieval was achieved using the ready-to-use Bond Epitope Retrieval Solution 1 (Leica Biosystems Newcastle, Ltd.) after 30 minutes of heating. C4d deposition on the elastic fibers of arterioles, arteries, and Glisson's capsule was regarded as a positive internal control. (4, 16) Two positive external controls were used. The first one was a liver allograft with known ABO-incompatible acute antibodymediated rejection (AMR) that exhibited diffuse microvascular staining. The second one was a kidney graft biopsy with cAMR that exhibited C4d staining score 3 (Supporting Fig. 1) . (17) C4d immunostaining was evaluated in a blind manner from clinical and histological data. Slides were first screened with a 203 objective NOTE: Data are given as n (%) or mean 6 standard deviation. *A total of 9 patients received 2 immunosuppressive drugs: calcineurin inhibitor 1 corticosteroid (n 5 6), calcineurin inhibitor 1 antimetabolite (n 5 3); 1 patient received calcineurin inhibitor 1 corticosteroid 1 antimetabolite. † Calcineurin inhibitors were prescribed to all children, but 2 of them were free of immunosuppressive drugs because they did not comply with their prescribed therapy. ‡ Mean ciclosporin through level 5 51 6 24 ng/mL. § Mean FK-506 through level 5 3.3 6 1.5 ng/mL. lens to assess the positivity of internal controls and to detect the presence of positive endothelium. C4d immunostaining was semiquantified for each type of endothelium (ie, portal vein and venule, portal capillary, centrilobular vein, and sinusoidal endothelial cells (18) ) with a 403 objective lens (Fig. 1) . Positivity for C4d staining was defined as linear/granular staining of endothelial cells all along the vascular section circumference. The semiquantitative score for each liver endothelium was adapted from the scoring system of the C4d expression in renal graft biopsies (18, 19) from stage 0 to 3 with stage 0, absence of immunostaining; stage 1, staining for <10% of the structures; stage 2, staining between 10% and 50% of the structures; and stage 3, staining for >50% of the structures. Portal C4d immunostaining score was defined as the sum of semiquantitative scores for portal vein/venule and capillary endothelial cells. Diffuse C4d deposition in portal stroma was considered to be a nonspecific finding without clinical significance because it was observed in 4 normal nontransplanted pediatric livers (data not shown).
ASSAYS FOR ANTI-HLA ANTIBODIES
Donors were typed for HLA system using commercially available serological methods (One Lambda, Inc., Canoga Park, CA). Loci A, B, DQ, and DR were typed. Blood samples were harvested from the recipients at the time of the liver biopsy. For the sake of the study, recipient anti-HLA antibodies were retrospectively analyzed by Luminex with the LABScreen single antigen class I and single antigen class II beads (LS1A04 and LS2A01, respectively; One Lambda, Inc.), after neutralization of the complement interference phenomenon using ethylene diamine tetraacetic acid before treatment of the serum, as described previously, (20) for all the samples that were found positive using the screening assay (LSM12; One Lambda, Inc.). Normalized mean fluorescence intensity (MFI) values of DSAs were reported, using the Baseline formula from the Fusion software. The specificities for both class I and class II HLA antibodies were considered positive for MFI > 1000, in accordance with the cutoff values often used in LT. (4, 5, 14) All crossmatches by lymphocytotoxicity were negative at the time of LT, but no information was available for the presence of pretransplant DSA.
FINAL DIAGNOSES
Four diagnosis patterns were defined from biochemical, pathological, and serological data:
1. Biliary obstruction defined by fibrous portal expansion associated with ductular reaction and neutrophilic inflammation. 2. Acute T cell-mediated rejection (TCMR) diagnosed and scored according to the Banff criteria.
3. Architecture/vascular changes defined by thickening of cell plates, foci of nodular regenerative hyperplasia, sinusoidal dilatation/congestion, and sinusoidal fibrosis.
4. Probable or possible cAMR diagnosed according to the 2016 Banff criteria. (13) None of the patients met the criteria for plasma cell-rich rejection or acute AMR. (13) 
STATISTICAL ANALYSES
Descriptive statistical methods (means, medians, standard deviations, and ranges) were used to assess the distributions of variables. Wilcoxon rank sum, t tests and Pearson's r product moment correlation were performed for continuous variables, Fisher's exact and chi-square tests for categorical variables. Univariate logistic regression and multivariate analyses were used with histologic data to predict both DSA positivity and portal C4d immunostaining score 2. Variables were eliminated for P values on univariate analysis >0.2 or concern for a lack of reproducibility in clinical practice. The final model produced a linear score. Receiver operating curve and area under the curve (AUC) were computed for this evaluation. For all analyses, a P value <0.05 was regarded as significant. All analyses were performed using the R software, version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria). (23) 
Results
HISTOLOGICAL FEATURES
Histological features of the 53 biopsies are summarized in Table 2 . None of the biopsies were strictly normal. All biopsies demonstrated fibrotic changes with a mean LAFSc of 5.1 6 2.2 (median, 5). Fibrosis was mainly sinusoidal (96%), perivenular (85%), and to a lesser degree portal (79%) (Fig. 2) . Moderate-to-severe perivenular fibrosis was present in 37 (70%) biopsies, including 13 biopsies with perivenulitis (Fig. 3) . Severe portal fibrosis was observed in 10 biopsies. It was always associated with portal tract collagenization as described by O'Leary et al. (9) (Supporting Fig. 2 ). Portal inflammation, which was present in 38 biopsies, was mild in 79% of biopsies, moderate in 16%, and severe in 5%. Portal inflammation was mainly represented by diffuse portal infiltrates with rare features of interface hepatitis. Portal "lymphoid" aggregates were observed in only 2 biopsies. None of the patients had either portal or sinusoidal microvasculitis. 
C4D IMMUNOSTAINING
C4d-positive internal control was seen in all biopsies. Twenty-two (42%) biopsies were totally negative for endothelial C4d immunostaining. Among the 31 biopsies that exhibited C4d positivity, 38% had a positive C4d immunostaining for sinusoidal cells, 15% for endothelial cells of portal veins and venules, 36% for endothelial cells of portal capillaries, and 21% for endothelial cells of centrilobular veins (Fig. 3) . The semiquantitative score for each liver endothelium is detailed in Table 3 .
DONOR-SPECIFIC ANTIBODY
Anti-HLA antibody analysis was performed in all patients. Donor HLA typing was available for 44 of the 53 patients (Fig. 4) . DSAs were detected in 20 among the 44 (45%) patients with available donor HLA typing. Two patients had anti-class I DSA alone (anti-A29 and anti-A1), 13 anti-class II DSA alone (anti-DQ2, -DQ3, -DQ5, -DQ6, -DQ7, -DQ9, -DR1, -DR7, -DR14, -DR51, -DR52, and -DR53), and 5 had both (anti-B49, -DQ6, -DQ8, and -DR53; anti-A2 and -DQ2 [n 5 2]; anti-A29, -DQ7, and -DQ8; anti-A2, -DR9, -DR13, -DR51, and -DR53). A total of 14 patients had more than 1 DSA. Mean maximal and total MFI were 12,977 6 6731 and 23,180 6 17,899, respectively. There was no significant demographic or clinical difference between the DSA-positive and DSAnegative patients.
FINAL DIAGNOSES
A conclusive histopathological pattern was achieved in 26 patients. Biliary obstruction was diagnosed in 8 patients. Acute TCMR was diagnosed in 3 patients with a Banff index 4. Architecture/vascular changes with nodular regenerative hyperplasia were observed in 8 patients. According to the 2016 Banff definition, cAMR was diagnosed in 13 patients (9 possible and 4 probable). Biliary obstruction and indeterminate acute cellular rejection were associated in 2 patients; architecture/vascular changes with nodular regenerative hyperplasia and possible cAMR were associated in 4 patients. All the patients with histological diagnosis of biliary obstruction underwent a cholangiography, which confirmed the presence of biliary stenosis.
HISTOLOGICAL FEATURES ASSOCIATED WITH C4D IMMUNOSTAINING
LAFSc and especially perivenular fibrosis were significantly higher in the biopsies with portal C4d 
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immunostaining score 2 (6.1 6 1.0 versus 4.9 6 2.4, P 5 0.01 and 2.4 6 0.5 versus 1.7 6 1.1, P 5 0.002, respectively; Supporting Table 1 ). Portal inflammation also trended to be higher (1.3 6 0.8 versus 0.8 6 0.7; P 5 0.09). C4d immunostaining for sinusoidal and centrilobular vein endothelial cells were not significantly associated with any histological feature. The histological diagnosis patterns of biliary obstruction, acute cellular rejection, and of architectural/vascular changes were not correlated with C4d immunostaining.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES ASSOCIATED WITH DSA
Histological features and C4d immunostaining in DSA-positive (n 5 20) and DSA-negative patients (n 5 24) are summarized in Supporting Table 2 . Portal inflammation was significantly increased (1.2 6 0.6 versus 0.7 6 0.8; P 5 0.02) in the DSA-positive group. LAFSc and especially perivenular fibrosis score tended to be higher (6.0 6 1.9 versus 4.8 6 2.3, P 5 0.057 and 2.2 6 1.0 versus 1.7 6 1.1, P 5 0.09, respectively) in the DSA-positive group. Moreover, the mean semiquantitative C4d score for portal endothelial cells and for sinusoidal cells were higher in the DSA-positive group (1.5 6 1.9 versus 0.5 6 0.9, P 5 0.04 and 0.9 6 0.8 versus 0.3 6 0.3, P 5 0.03, respectively). The histological diagnosis patterns of biliary obstruction, acute cellular rejection, and of architectural/vascular changes were not correlated with DSA.
MORPHOLOGICAL FEATURES IN PATIENTS WITH EXTREME PHENOTYPES (C4D1 DSA1/C4D-DSA-)
To better define the morphological lesions associated with cAMR in pediatric liver graft recipients, we compared patients with extreme phenotypes: "doublepositive" patients (n 5 7), who had both DSA and portal C4d immunostaining score 2, versus "double- negative" patients (n 5 12), negative for DSA and C4d (Table 4) . In univariate analysis, LAFSc (6.3 6 1.3 versus 3.9 6 2.2; P 5 0.008), perivenular fibrosis (2.7 6 0.5 versus 1.3 6 1.0; P < 0.001), and portal inflammation (1.4 6 0.8 versus 0.3 6 0.5; P 5 0.009) were significantly higher in the double-positive group. In multivariate analysis, perivenular fibrosis and portal inflammation remained significantly higher in doublepositive patients and lobular inflammation tended to be higher (P 5 0.06). These 3 items were included into a predictive model. The model was calculated as 0.20 (perivenular fibrosis) 1 0.33 (portal inflammation) 1 0.15 (lobular inflammation), where factors were scored from 0 to 3 as previously described. This score was significantly higher in double-positive patients (1.2 6 0.3 versus 0.4 6 0.2; P < 0.001). Its original AUC was 99%. Cutoff value of 0.665 allowed to differentiate "double-positive" and "doublenegative" patients. This cutoff value had a specificity of 92% and a sensitivity of 100%. Of the 53 patients, 30 had a histological score issued from the doublepositive and the double-negative patients higher than the cutoff of 0.665. This score issued from the doublepositive and the double-negative patients was introduced as a binary criterion (> or <0.665) in place of the histological criteria of the Banff 2016 algorithm for the diagnosis of cAMR for all patients. The diagnosis of cAMR was confirmed in 11/13 patients. Diagnoses of probable cAMR according to Banff 2016 were unchanged (n 5 4), but diagnoses of possible cAMR according to Banff 2016 were not retained for 2 among the 9 patients (Fig. 5 ). Among the 19 other patients with a positive histological score (>0.665), the final diagnosis was biliary obstruction in 5 patients and acute TCMR in 1 patient. No definite diagnosis was achieved in 13 patients, 9 were negative for DSA, and 4 patients did not have available DSA (Supporting Fig. 3 ).
Discussion
The cAMR is more and more identified as an issue in LT. Diagnosis criteria for probable liver allograft 
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cAMR were first introduced by the Banff working group on liver allograft pathology in 2016. (13) These criteria include the 2 classical markers for humoral immune response (ie, presence of DSA and C4d portal microvasculature deposits) and histological features. However, the histological features cover a very large spectrum of lesions and need to be refined. With the aim of better defining cAMR, we studied the 10-year protocol biopsies from 53 liver pediatric ABOidentical or compatible recipients to delimitate the morphological changes specifically associated with the presence of DSA and C4d immunostaining in liver grafts. Indeed, as suggested by the Banff working group, pediatric liver graft recipients represent an "ideal model" to identify pure rejection-induced morphological lesions because they do not suffer from recurrence of the initial liver disease and are usually free of comorbidities as nonalcoholic fatty liver disease. According to the last Banff criteria, (13) the diagnosis of probable (n 5 9) or possible (n 5 4) cAMR was made in 13/53 (25%) patients. In adult recipients, there is not yet any report about the real incidence of cAMR 10 years after the transplantation according to these recently published diagnostic criteria. It is likely to be lower than in the pediatric population, reflecting another difference between pediatric and adult liver graft recipients. Despite the absence of recurrence in initial liver disease in pediatric transplantation, smaller allograft sizes decrease antibody adsorption, and the immaturity of the immune system increases alloantibody production, which altogether generate ideal conditions for the development of AMR rejection. (13) With a MFI cutoff above 1000, which has been recently accepted to define the presence of clinically relevant DSA especially in pediatric recipients, (4, 24) 45% of our pediatric patients were considered as positive for DSA at 10 years after transplantation. The same frequency was observed by Miyagawa-Hayashino et al. (4) In adult liver recipients, there are few data about the DSA frequency at 10 years after transplantation, (5, 10, 14) but it seems to be lower. O'Leary et al. (12) recently studied the incidence of DSA in a cohort of 850 adult liver recipients: 31% of them had DSAs at 1 year after transplantation. Also, 97% of patients with high MFI DSAs (>10,000) at 1 year showed DSA persistence at 5 years, but nearly 40% of patients with low MFI DSA (1000-4999) became negative (<1000) by 5 years. The second marker of AMR among the Banff criteria is the presence of C4d microvasculature deposits. However, the interpretation of C4d immunostaining is difficult on liver graft biopsies. Immunofluorescence on frozen sections remains the gold standard for kidney graft biopsies. Similarly, the sensitivity of C4d staining on liver grafts is lower on paraffin sections than in the frozen sections. (25) In addition, the interpretation of C4d staining on liver tissue is difficult because of the diversity of the targeted structures. In our series, as in most other studies, (13, 26) only C4d immunostaining of portal vein/venule and capillary endothelial cells appears meaningful for the diagnosis of cAMR because it was significantly associated with both histological lesions and DSA. In our cohort of pediatric recipients, the histological lesions associated with portal C4d immunostaining score 2 were LAFSc and perivenular fibrosis. Portal inflammation also tended to be higher. In the DSA-positive group, portal inflammation significantly increased and LAFSc, especially perivenular fibrosis, tended to be higher. Moreover, the mean semiquantitative scores for portal endothelial cells and for sinusoidal cells were significantly higher in the DSA-positive group, but C4d immunostaining for sinusoidal cells was not significantly associated with any histological features.
FIG. 5.
Histological score was used to refine the cAMR diagnosis. *Banff cAMR could not be assessed when histological features exhibited some diagnosis criteria for cAMR, whereas DSA data were lacking.
§Although histological features could be consistent with cAMR according to the 2016 Banff criteria, histological score was < 0.665 and allowed to exclude the diagnostic of cAMR.
Several previous studies in pediatric recipients demonstrated a correlation between perivenular fibrosis and circulating DSA and/or C4d endothelial staining. (4, 16, 27, 28) The development and progression of graft fibrosis, which occurs in 57%-97%, (3, 22, (29) (30) (31) (32) long after the resolution of early complications, is a major emerging concern in longterm outcomes following pediatric LT. Our results support the notion that this may be a manifestation of cAMR.
In adult recipients, the histological lesions associated with high MFI DSA and included in a recently proposed cAMR score (9, 12) are more complex and various: lobular inflammation, interface hepatitis, portal collagenization, portal venopathy, and subsinusoidal fibrosis. However, the presence of hepatitis C virus viremia in more than 50% of the patients probably blurred the histological picture specifically linked to AMR. Portal inflammation appears as a common manifestation of cAMR in adult and pediatric recipients. Conversely, perivenular fibrosis which appears to be the major lesion in pediatric recipients is not highlighted as a feature of cAMR in adult recipients.
To increase the accuracy of the histological changes specific for cAMR, we developed a histopathological score, including perivenular fibrosis, portal inflammation, and lobular inflammation. Among the 53 patients, 30 had a histological score of >0.665, which is predictive for both portal C4d and DSA positivity. The integration of this histological score into the Banff criteria allowed for classification of patients into probable and possible cAMR. Among the 9 patients initially classified as possible cAMR, 2 were excluded for this diagnostic process. From a practical point of view, the histopathological score we proposed herein would allow the accurate identification of pediatric recipients with DSA at risk of cAMR in order to appropriately tailor their immunosuppressive treatment.
In adult liver recipients, a cAMR score has been published and validated to predict graft failure. (9, 12) In pediatric recipients, perivenular fibrosis, which appears to be a major feature of cAMR, has so far not been associated with any graft functional loss. A recent study from our group (1) reported the longterm followup (mean, 24 years) of a cohort of 128 patients who received a liver allograft in childhood. Graft histology was available for 35 patients with a mean interval of 21 years after transplantation. A total of 9 were diagnosed as chronic rejection, mainly on the basis of the presence of moderate-to-severe centrilobular fibrosis. Of the 9 late retransplantations, 4 were due to chronic rejection. A total of 28 patients underwent 2 successive biopsies between 10 and 20 years after transplantation. Progression 2 digits of the total fibrosis score was observed in 8 patients (including 2 chronic rejections). Improvement 2 digits of the total fibrosis score was observed in 3 patients who were switched from cyclosporine A (CsA) to tacrolimus (FK-506) for chronic rejection diagnosed on the 10-year liver biopsy. These results highlight the deleterious effects of chronic rejection demonstrated by perivenular fibrosis on liver grafts and the beneficial role of immunosuppressive treatment adaptation.
In conclusion, our study based on a cohort of 53 liver pediatric ABO-identical or compatible recipients with a 10-year protocol biopsy strongly suggests that perivenular fibrosis and portal inflammation are the main histological features associated with cAMR. Further investigations are needed to extrapolate these results to adult liver graft recipients.
